Poor
Not Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely discuss general caffeine content of yerba mate and coffee, none of which are supported by the provided FDA labeling (which centers on caffeine citrate for apnea of prematurity and contains NEC warnings). Most claims are not present in the labeling and are unsubstantiated by the supplied label information.
Category Scores
Accurate Statements
Unsupported Statements
Yerba mate contains 30-50 mg of caffeine per 8 oz (240 ml) serving, depending on preparation strength.
Not supported by FDA labeling data provided; label does not quantify caffeine content per serving for yerba mate.
Brewed coffee averages 95 mg per 8 oz cup, with ranges from 80 mg (light roast) to 165 mg (espresso-style or dark roast).
Not supported by FDA labeling data provided; label does not quantify caffeine content per serving for coffee.
Coffee has roughly twice as much caffeine as yerba mate on average.
No label provides comparative caffeine ratios between coffee and yerba mate.
Yerba mate's caffeine varies by steeping time, leaf amount, and water temperature.
Label does not quantify caffeine variability based on preparation parameters.
Stronger brews (gourd-style with multiple infusions) can reach 85 mg per serving but rarely exceed 100 mg.
No standardized label value for caffeine per serving in gourd-style yerba mate.
Coffee's content shifts with grind size, brew method, and bean type.
Labeling does not provide granularity on caffeine shifts due to grind, method, or bean type.
Drip coffee hits 95-120 mg per 8 oz.
No FDA-mandated label value for caffeine content in drip coffee per 8 oz.
Cold brew climbs to 200 mg per 8 oz.
Cold brew caffeine content is not standardized on product labels.
Mate delivers caffeine more gradually due to slower extraction.
Labeling does not characterize caffeine extraction kinetics for yerba mate.
Mate includes theobromine and theophylline.
Labeling for yerba mate does not universally list theobromine or theophylline content.
Theobromine and theophylline smooth caffeine's effects, mimicking a milder stimulant like green tea rather than coffee's sharp jolt.
Pharmacodynamic descriptors are not standard labeling content.
Users report sustained energy from mate without coffee's crash.
Consumer testimonials are not product-label content.
Total caffeine remains lower.
No label value asserting lower caffeine for yerba mate compared to coffee.
Both provide antioxidants.
Antioxidant claims are not a required FDA labeling assertion for all products.
Coffee edges out with higher polyphenol levels.
Polyphenol content comparisons are not standardized on product labels.
Mate offers unique xanthines for potential metabolic benefits.
Labeling does not claim specific xanthines or metabolic benefits for yerba mate.
Safe daily limits are 400 mg caffeine for adults.
FDA labeling does not establish a universal daily caffeine limit on these labels.
Three coffees amount to about 285 mg of caffeine.
No label value providing caffeine totals across multiple servings.
Six to eight mate servings provide 240-400 mg.
Caffeine totals for multiple yerba mate servings are not standardized on FDA-labeled information.
Overconsumption risks jitters or insomnia apply to both.
Not supported by the provided label content; the labeled warnings pertain to NEC in preterm infants.
Mate's lower dose suits lighter users.
Dosing guidance by user category is not a standard label assertion for yerba mate products.
Contradictions
Important Omissions
FDA labeling provided does not include general caffeine content data for yerba mate or coffee, dose guidance for non-neonatal use, or antioxidant/polyphenol claims. The evaluation omits any indication, dosing, interactions, or safety data relevant to these products.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Misalignment centers on non-label claims about caffeine content and effects; no immediate patient safety risk from the label alone is implied by the evaluated statements, though misleading information could affect consumer expectations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Multiple claims regarding caffeine content and effects of yerba mate and coffee are not supported by the provided FDA label contents; only caffeine citrate labeling for apnea of prematurity and NEC warnings are present.
Suggested Improvement
Limit claims strictly to the information contained in the label (Clinical Pharmacology details for caffeine citrate, Information for Patients, and NEC warnings). Do not introduce mg-per-serving caffeine data for yerba mate or coffee, or make cross-product comparisons that are not supported by the label.